Summary
According to APO Research, The global Cone-rod Dystrophy Treatment market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Cone-rod Dystrophy Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Cone-rod Dystrophy Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Cone-rod Dystrophy Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Cone-rod Dystrophy Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Cone-rod Dystrophy Treatment include JCyte, Nanoscope Therapeutics, SparingVision, MeiraGTx, AGTC, Biogen, Second Sight Medical, GlaxoSmithKline and Johnson And Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Cone-rod Dystrophy Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Cone-rod Dystrophy Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Cone-rod Dystrophy Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cone-rod Dystrophy Treatment revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Cone-rod Dystrophy Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Cone-rod Dystrophy Treatment revenue, projected growth trends, production technology, application and end-user industry.
Cone-rod Dystrophy Treatment segment by Company
JCyte
Nanoscope Therapeutics
SparingVision
MeiraGTx
AGTC
Biogen
Second Sight Medical
GlaxoSmithKline
Johnson And Johnson
Sanofi
Pfizer
Novartis
Abbott Laboratories
Cone-rod Dystrophy Treatment segment by Type
Gene Therapy
Stem Cell Therapy
Retinal Implant Surgery
Cone-rod Dystrophy Treatment segment by Application
Hospital
Ophthalmology Department
Other
Cone-rod Dystrophy Treatment segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cone-rod Dystrophy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cone-rod Dystrophy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cone-rod Dystrophy Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Cone-rod Dystrophy Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Cone-rod Dystrophy Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cone-rod Dystrophy Treatment revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Cone-rod Dystrophy Treatment Market by Type
1.2.1 Global Cone-rod Dystrophy Treatment Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Gene Therapy
1.2.3 Stem Cell Therapy
1.2.4 Retinal Implant Surgery
1.3 Cone-rod Dystrophy Treatment Market by Application
1.3.1 Global Cone-rod Dystrophy Treatment Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Ophthalmology Department
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Cone-rod Dystrophy Treatment Market Dynamics
2.1 Cone-rod Dystrophy Treatment Industry Trends
2.2 Cone-rod Dystrophy Treatment Industry Drivers
2.3 Cone-rod Dystrophy Treatment Industry Opportunities and Challenges
2.4 Cone-rod Dystrophy Treatment Industry Restraints
3 Global Growth Perspective
3.1 Global Cone-rod Dystrophy Treatment Market Perspective (2019-2030)
3.2 Global Cone-rod Dystrophy Treatment Growth Trends by Region
3.2.1 Global Cone-rod Dystrophy Treatment Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Cone-rod Dystrophy Treatment Market Size by Region (2019-2024)
3.2.3 Global Cone-rod Dystrophy Treatment Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Cone-rod Dystrophy Treatment Revenue by Players
4.1.1 Global Cone-rod Dystrophy Treatment Revenue by Players (2019-2024)
4.1.2 Global Cone-rod Dystrophy Treatment Revenue Market Share by Players (2019-2024)
4.1.3 Global Cone-rod Dystrophy Treatment Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Cone-rod Dystrophy Treatment Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Cone-rod Dystrophy Treatment Key Players Headquarters & Area Served
4.4 Global Cone-rod Dystrophy Treatment Players, Product Type & Application
4.5 Global Cone-rod Dystrophy Treatment Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Cone-rod Dystrophy Treatment Market CR5 and HHI
4.6.2 Global Top 5 and 10 Cone-rod Dystrophy Treatment Players Market Share by Revenue in 2023
4.6.3 2023 Cone-rod Dystrophy Treatment Tier 1, Tier 2, and Tier 3
5 Cone-rod Dystrophy Treatment Market Size by Type
5.1 Global Cone-rod Dystrophy Treatment Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Cone-rod Dystrophy Treatment Revenue by Type (2019-2030)
5.3 Global Cone-rod Dystrophy Treatment Revenue Market Share by Type (2019-2030)
6 Cone-rod Dystrophy Treatment Market Size by Application
6.1 Global Cone-rod Dystrophy Treatment Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Cone-rod Dystrophy Treatment Revenue by Application (2019-2030)
6.3 Global Cone-rod Dystrophy Treatment Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 JCyte
7.1.1 JCyte Comapny Information
7.1.2 JCyte Business Overview
7.1.3 JCyte Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.1.4 JCyte Cone-rod Dystrophy Treatment Product Portfolio
7.1.5 JCyte Recent Developments
7.2 Nanoscope Therapeutics
7.2.1 Nanoscope Therapeutics Comapny Information
7.2.2 Nanoscope Therapeutics Business Overview
7.2.3 Nanoscope Therapeutics Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.2.4 Nanoscope Therapeutics Cone-rod Dystrophy Treatment Product Portfolio
7.2.5 Nanoscope Therapeutics Recent Developments
7.3 SparingVision
7.3.1 SparingVision Comapny Information
7.3.2 SparingVision Business Overview
7.3.3 SparingVision Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.3.4 SparingVision Cone-rod Dystrophy Treatment Product Portfolio
7.3.5 SparingVision Recent Developments
7.4 MeiraGTx
7.4.1 MeiraGTx Comapny Information
7.4.2 MeiraGTx Business Overview
7.4.3 MeiraGTx Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.4.4 MeiraGTx Cone-rod Dystrophy Treatment Product Portfolio
7.4.5 MeiraGTx Recent Developments
7.5 AGTC
7.5.1 AGTC Comapny Information
7.5.2 AGTC Business Overview
7.5.3 AGTC Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.5.4 AGTC Cone-rod Dystrophy Treatment Product Portfolio
7.5.5 AGTC Recent Developments
7.6 Biogen
7.6.1 Biogen Comapny Information
7.6.2 Biogen Business Overview
7.6.3 Biogen Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.6.4 Biogen Cone-rod Dystrophy Treatment Product Portfolio
7.6.5 Biogen Recent Developments
7.7 Second Sight Medical
7.7.1 Second Sight Medical Comapny Information
7.7.2 Second Sight Medical Business Overview
7.7.3 Second Sight Medical Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.7.4 Second Sight Medical Cone-rod Dystrophy Treatment Product Portfolio
7.7.5 Second Sight Medical Recent Developments
7.8 GlaxoSmithKline
7.8.1 GlaxoSmithKline Comapny Information
7.8.2 GlaxoSmithKline Business Overview
7.8.3 GlaxoSmithKline Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.8.4 GlaxoSmithKline Cone-rod Dystrophy Treatment Product Portfolio
7.8.5 GlaxoSmithKline Recent Developments
7.9 Johnson And Johnson
7.9.1 Johnson And Johnson Comapny Information
7.9.2 Johnson And Johnson Business Overview
7.9.3 Johnson And Johnson Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.9.4 Johnson And Johnson Cone-rod Dystrophy Treatment Product Portfolio
7.9.5 Johnson And Johnson Recent Developments
7.10 Sanofi
7.10.1 Sanofi Comapny Information
7.10.2 Sanofi Business Overview
7.10.3 Sanofi Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.10.4 Sanofi Cone-rod Dystrophy Treatment Product Portfolio
7.10.5 Sanofi Recent Developments
7.11 Pfizer
7.11.1 Pfizer Comapny Information
7.11.2 Pfizer Business Overview
7.11.3 Pfizer Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.11.4 Pfizer Cone-rod Dystrophy Treatment Product Portfolio
7.11.5 Pfizer Recent Developments
7.12 Novartis
7.12.1 Novartis Comapny Information
7.12.2 Novartis Business Overview
7.12.3 Novartis Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.12.4 Novartis Cone-rod Dystrophy Treatment Product Portfolio
7.12.5 Novartis Recent Developments
7.13 Abbott Laboratories
7.13.1 Abbott Laboratories Comapny Information
7.13.2 Abbott Laboratories Business Overview
7.13.3 Abbott Laboratories Cone-rod Dystrophy Treatment Revenue and Gross Margin (2019-2024)
7.13.4 Abbott Laboratories Cone-rod Dystrophy Treatment Product Portfolio
7.13.5 Abbott Laboratories Recent Developments
8 North America
8.1 North America Cone-rod Dystrophy Treatment Revenue (2019-2030)
8.2 North America Cone-rod Dystrophy Treatment Revenue by Type (2019-2030)
8.2.1 North America Cone-rod Dystrophy Treatment Revenue by Type (2019-2024)
8.2.2 North America Cone-rod Dystrophy Treatment Revenue by Type (2025-2030)
8.3 North America Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
8.4 North America Cone-rod Dystrophy Treatment Revenue by Application (2019-2030)
8.4.1 North America Cone-rod Dystrophy Treatment Revenue by Application (2019-2024)
8.4.2 North America Cone-rod Dystrophy Treatment Revenue by Application (2025-2030)
8.5 North America Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
8.6 North America Cone-rod Dystrophy Treatment Revenue by Country
8.6.1 North America Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Cone-rod Dystrophy Treatment Revenue by Country (2019-2024)
8.6.3 North America Cone-rod Dystrophy Treatment Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Cone-rod Dystrophy Treatment Revenue (2019-2030)
9.2 Europe Cone-rod Dystrophy Treatment Revenue by Type (2019-2030)
9.2.1 Europe Cone-rod Dystrophy Treatment Revenue by Type (2019-2024)
9.2.2 Europe Cone-rod Dystrophy Treatment Revenue by Type (2025-2030)
9.3 Europe Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
9.4 Europe Cone-rod Dystrophy Treatment Revenue by Application (2019-2030)
9.4.1 Europe Cone-rod Dystrophy Treatment Revenue by Application (2019-2024)
9.4.2 Europe Cone-rod Dystrophy Treatment Revenue by Application (2025-2030)
9.5 Europe Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
9.6 Europe Cone-rod Dystrophy Treatment Revenue by Country
9.6.1 Europe Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Cone-rod Dystrophy Treatment Revenue by Country (2019-2024)
9.6.3 Europe Cone-rod Dystrophy Treatment Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Cone-rod Dystrophy Treatment Revenue (2019-2030)
10.2 China Cone-rod Dystrophy Treatment Revenue by Type (2019-2030)
10.2.1 China Cone-rod Dystrophy Treatment Revenue by Type (2019-2024)
10.2.2 China Cone-rod Dystrophy Treatment Revenue by Type (2025-2030)
10.3 China Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
10.4 China Cone-rod Dystrophy Treatment Revenue by Application (2019-2030)
10.4.1 China Cone-rod Dystrophy Treatment Revenue by Application (2019-2024)
10.4.2 China Cone-rod Dystrophy Treatment Revenue by Application (2025-2030)
10.5 China Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Cone-rod Dystrophy Treatment Revenue (2019-2030)
11.2 Asia Cone-rod Dystrophy Treatment Revenue by Type (2019-2030)
11.2.1 Asia Cone-rod Dystrophy Treatment Revenue by Type (2019-2024)
11.2.2 Asia Cone-rod Dystrophy Treatment Revenue by Type (2025-2030)
11.3 Asia Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
11.4 Asia Cone-rod Dystrophy Treatment Revenue by Application (2019-2030)
11.4.1 Asia Cone-rod Dystrophy Treatment Revenue by Application (2019-2024)
11.4.2 Asia Cone-rod Dystrophy Treatment Revenue by Application (2025-2030)
11.5 Asia Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
11.6 Asia Cone-rod Dystrophy Treatment Revenue by Country
11.6.1 Asia Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Cone-rod Dystrophy Treatment Revenue by Country (2019-2024)
11.6.3 Asia Cone-rod Dystrophy Treatment Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Cone-rod Dystrophy Treatment Revenue (2019-2030)
12.2 MEALA Cone-rod Dystrophy Treatment Revenue by Type (2019-2030)
12.2.1 MEALA Cone-rod Dystrophy Treatment Revenue by Type (2019-2024)
12.2.2 MEALA Cone-rod Dystrophy Treatment Revenue by Type (2025-2030)
12.3 MEALA Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
12.4 MEALA Cone-rod Dystrophy Treatment Revenue by Application (2019-2030)
12.4.1 MEALA Cone-rod Dystrophy Treatment Revenue by Application (2019-2024)
12.4.2 MEALA Cone-rod Dystrophy Treatment Revenue by Application (2025-2030)
12.5 MEALA Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
12.6 MEALA Cone-rod Dystrophy Treatment Revenue by Country
12.6.1 MEALA Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Cone-rod Dystrophy Treatment Revenue by Country (2019-2024)
12.6.3 MEALA Cone-rod Dystrophy Treatment Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Cone-rod Dystrophy Treatment Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Gene Therapy Major Manufacturers
Table 2. Stem Cell Therapy Major Manufacturers
Table 3. Retinal Implant Surgery Major Manufacturers
Table 4. Global Cone-rod Dystrophy Treatment Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Hospital Major Manufacturers
Table 6. Ophthalmology Department Major Manufacturers
Table 7. Other Major Manufacturers
Table 8. Cone-rod Dystrophy Treatment Industry Trends
Table 9. Cone-rod Dystrophy Treatment Industry Drivers
Table 10. Cone-rod Dystrophy Treatment Industry Opportunities and Challenges
Table 11. Cone-rod Dystrophy Treatment Industry Restraints
Table 12. Global Cone-rod Dystrophy Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Cone-rod Dystrophy Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Cone-rod Dystrophy Treatment Market Share by Region (2019-2024)
Table 15. Global Cone-rod Dystrophy Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Cone-rod Dystrophy Treatment Market Share by Region (2025-2030)
Table 17. Global Cone-rod Dystrophy Treatment Revenue by Players (US$ Million) & (2019-2024)
Table 18. Global Cone-rod Dystrophy Treatment Revenue Market Share by Players (2019-2024)
Table 19. Global Cone-rod Dystrophy Treatment Key Players Ranking, 2022 VS 2023 VS 2024
Table 20. Global Cone-rod Dystrophy Treatment Key Players Headquarters & Area Served
Table 21. Global Cone-rod Dystrophy Treatment Players, Product Type & Application
Table 22. Global Cone-rod Dystrophy Treatment Players Commercialization Time
Table 23. Global Players Market Concentration Ratio (CR5 and HHI)
Table 24. Global Cone-rod Dystrophy Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 25. Global Cone-rod Dystrophy Treatment Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 26. Global Cone-rod Dystrophy Treatment Revenue by Type (2019-2024) & (US$ Million)
Table 27. Global Cone-rod Dystrophy Treatment Revenue by Type (2025-2030) & (US$ Million)
Table 28. Global Cone-rod Dystrophy Treatment Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 29. Global Cone-rod Dystrophy Treatment Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 30. Global Cone-rod Dystrophy Treatment Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Global Cone-rod Dystrophy Treatment Revenue by Application (2019-2024) & (US$ Million)
Table 32. Global Cone-rod Dystrophy Treatment Revenue by Application (2025-2030) & (US$ Million)
Table 33. Global Cone-rod Dystrophy Treatment Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 34. Global Cone-rod Dystrophy Treatment Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 35. JCyte Company Information
Table 36. JCyte Business Overview
Table 37. JCyte Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 38. JCyte Cone-rod Dystrophy Treatment Product Portfolio
Table 39. JCyte Recent Development
Table 40. Nanoscope Therapeutics Company Information
Table 41. Nanoscope Therapeutics Business Overview
Table 42. Nanoscope Therapeutics Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 43. Nanoscope Therapeutics Cone-rod Dystrophy Treatment Product Portfolio
Table 44. Nanoscope Therapeutics Recent Development
Table 45. SparingVision Company Information
Table 46. SparingVision Business Overview
Table 47. SparingVision Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 48. SparingVision Cone-rod Dystrophy Treatment Product Portfolio
Table 49. SparingVision Recent Development
Table 50. MeiraGTx Company Information
Table 51. MeiraGTx Business Overview
Table 52. MeiraGTx Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 53. MeiraGTx Cone-rod Dystrophy Treatment Product Portfolio
Table 54. MeiraGTx Recent Development
Table 55. AGTC Company Information
Table 56. AGTC Business Overview
Table 57. AGTC Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 58. AGTC Cone-rod Dystrophy Treatment Product Portfolio
Table 59. AGTC Recent Development
Table 60. Biogen Company Information
Table 61. Biogen Business Overview
Table 62. Biogen Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 63. Biogen Cone-rod Dystrophy Treatment Product Portfolio
Table 64. Biogen Recent Development
Table 65. Second Sight Medical Company Information
Table 66. Second Sight Medical Business Overview
Table 67. Second Sight Medical Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 68. Second Sight Medical Cone-rod Dystrophy Treatment Product Portfolio
Table 69. Second Sight Medical Recent Development
Table 70. GlaxoSmithKline Company Information
Table 71. GlaxoSmithKline Business Overview
Table 72. GlaxoSmithKline Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 73. GlaxoSmithKline Cone-rod Dystrophy Treatment Product Portfolio
Table 74. GlaxoSmithKline Recent Development
Table 75. Johnson And Johnson Company Information
Table 76. Johnson And Johnson Business Overview
Table 77. Johnson And Johnson Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 78. Johnson And Johnson Cone-rod Dystrophy Treatment Product Portfolio
Table 79. Johnson And Johnson Recent Development
Table 80. Sanofi Company Information
Table 81. Sanofi Business Overview
Table 82. Sanofi Cone-rod Dystrophy Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 83. Sanofi Cone-rod Dystrophy Treatment Product Portfolio
Table 84. Sanofi Recent Development
Table 85. Pfizer Company Information
Table 86. Pfizer Business Overview
Table 87. Pfizer Cone-rod Dystrophy Treatment Sales (), Revenue (US$ Million), Price () and Gross Margin (2019-2024)
Table 88. Pfizer Cone-rod Dystrophy Treatment Product Portfolio
Table 89. Pfizer Recent Development
Table 90. Novartis Company Information
Table 91. Novartis Business Overview
Table 92. Novartis Cone-rod Dystrophy Treatment Sales (), Revenue (US$ Million), Price () and Gross Margin (2019-2024)
Table 93. Novartis Cone-rod Dystrophy Treatment Product Portfolio
Table 94. Novartis Recent Development
Table 95. Abbott Laboratories Company Information
Table 96. Abbott Laboratories Business Overview
Table 97. Abbott Laboratories Cone-rod Dystrophy Treatment Sales (), Revenue (US$ Million), Price () and Gross Margin (2019-2024)
Table 98. Abbott Laboratories Cone-rod Dystrophy Treatment Product Portfolio
Table 99. Abbott Laboratories Recent Development
Table 100. North America Cone-rod Dystrophy Treatment Revenue by Type (2019-2024) & (US$ Million)
Table 101. North America Cone-rod Dystrophy Treatment Revenue by Application (2019-2024) & (US$ Million)
Table 102. North America Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 103. North America Cone-rod Dystrophy Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 104. North America Cone-rod Dystrophy Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 105. Europe Cone-rod Dystrophy Treatment Revenue by Type (2019-2024) & (US$ Million)
Table 106. Europe Cone-rod Dystrophy Treatment Revenue by Application (2019-2024) & (US$ Million)
Table 107. Europe Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 108. Europe Cone-rod Dystrophy Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 109. Europe Cone-rod Dystrophy Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 110. China Cone-rod Dystrophy Treatment Revenue by Type (2019-2024) & (US$ Million)
Table 111. China Cone-rod Dystrophy Treatment Revenue by Application (2019-2024) & (US$ Million)
Table 112. Asia Cone-rod Dystrophy Treatment Revenue by Type (2019-2024) & (US$ Million)
Table 113. Asia Cone-rod Dystrophy Treatment Revenue by Application (2019-2024) & (US$ Million)
Table 114. Asia Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 115. Asia Cone-rod Dystrophy Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 116. Asia Cone-rod Dystrophy Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 117. MEALA Cone-rod Dystrophy Treatment Revenue by Type (2019-2024) & (US$ Million)
Table 118. MEALA Cone-rod Dystrophy Treatment Revenue by Application (2019-2024) & (US$ Million)
Table 119. MEALA Cone-rod Dystrophy Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 120. MEALA Cone-rod Dystrophy Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 121. MEALA Cone-rod Dystrophy Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 122. Research Programs/Design for This Report
Table 123. Authors List of This Report
Table 124. Secondary Sources
Table 125. Primary Sources
List of Figures
Figure 1. Cone-rod Dystrophy Treatment Product Picture
Figure 2. Global Cone-rod Dystrophy Treatment Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Cone-rod Dystrophy Treatment Market Size Share 2019 VS 2023 VS 2030
Figure 4. Gene Therapy Picture
Figure 5. Stem Cell Therapy Picture
Figure 6. Retinal Implant Surgery Picture
Figure 7. Global Cone-rod Dystrophy Treatment Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 8. Global Cone-rod Dystrophy Treatment Market Size Share 2019 VS 2023 VS 2030
Figure 9. Hospital Picture
Figure 10. Ophthalmology Department Picture
Figure 11. Other Picture
Figure 12. Global Cone-rod Dystrophy Treatment Market Size (US$ Million) & (2019-2030)
Figure 13. Global Cone-rod Dystrophy Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Cone-rod Dystrophy Treatment Market Share by Region: 2019 VS 2023 VS 2030
Figure 15. Global Cone-rod Dystrophy Treatment Players Revenue Share Top 10 and Top 5 in 2023
Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 17. Global Cone-rod Dystrophy Treatment Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Cone-rod Dystrophy Treatment Revenue Market Share 2019 VS 2023 VS 2030
Figure 19. Global Cone-rod Dystrophy Treatment Revenue Market Share by Type (2019-2030)
Figure 20. Global Cone-rod Dystrophy Treatment Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Cone-rod Dystrophy Treatment Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 22. Global Cone-rod Dystrophy Treatment Revenue Market Share by Application (2019-2030)
Figure 23. North America Cone-rod Dystrophy Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Cone-rod Dystrophy Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 25. North America Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
Figure 26. North America Cone-rod Dystrophy Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 27. North America Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
Figure 28. North America Cone-rod Dystrophy Treatment Revenue Share by Country (2019-2030)
Figure 29. United States Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 30. Canada Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Europe Cone-rod Dystrophy Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 32. Europe Cone-rod Dystrophy Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 33. Europe Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
Figure 34. Europe Cone-rod Dystrophy Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 35. Europe Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
Figure 36. Europe Cone-rod Dystrophy Treatment Revenue Share by Country (2019-2030)
Figure 37. Germany Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 38. France Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. U.K. Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. Italy Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Russia Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Nordic Countries Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. China Cone-rod Dystrophy Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 44. China Cone-rod Dystrophy Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 45. China Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
Figure 46. China Cone-rod Dystrophy Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 47. China Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
Figure 48. Asia Cone-rod Dystrophy Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 49. Asia Cone-rod Dystrophy Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 50. Asia Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
Figure 51. Asia Cone-rod Dystrophy Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 52. Asia Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
Figure 53. Asia Cone-rod Dystrophy Treatment Revenue Share by Country (2019-2030)
Figure 54. Japan Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 55. South Korea Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. India Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. Australia Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. China Taiwan Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. Southeast Asia Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. MEALA Cone-rod Dystrophy Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 61. MEALA Cone-rod Dystrophy Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 62. MEALA Cone-rod Dystrophy Treatment Revenue Share by Type (2019-2030)
Figure 63. MEALA Cone-rod Dystrophy Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 64. MEALA Cone-rod Dystrophy Treatment Revenue Share by Application (2019-2030)
Figure 65. MEALA Cone-rod Dystrophy Treatment Revenue Share by Country (2019-2030)
Figure 66. Mexico Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 67. South Korea Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. Brazil Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Israel Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Argentina Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Colombia Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Turkey Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Saudi Arabia Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. UAE Cone-rod Dystrophy Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Years Considered
Figure 76. Research Process
Figure 77. Key Executives Interviewed
